Basic science and clinical research initiatives play a critical role in our mission to eradicate ovarian cancer. At MD Anderson, findings in the laboratory are quickly translated to the clinics, offering patients access to innovative new therapies and the opportunity to participate in clinical trials not available elsewhere. Support from major federal grants and private philanthropy have fueled this progress.
Among the numerous grants we have received for research into ovarian cancer are a $1.2 million grant from the Department of Defense as well as a $10 million five-year Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute.
Department of Defense Grant
In 1999, the Blanton-Davis Ovarian Cancer Research Program received a four-year, $1.2 million grant from the Department of Defense. These funds support research focusing on the chemoprevention of ovarian cancer.
In 1999, the National Cancer Institute awarded MD Anderson a $10 million, five-year SPORE grant, which recognizes Specialized Programs of Research Excellence. This grant facilitates innovative research into the prevention, detection and treatment of ovarian cancer by funding basic science and clinical research in four areas: the study of chemoprevention, evaluation of angiogenic factors, examination of tumor suppressor genes and investigation of tumor inhibiting factors. The grant also provides start-up funds for young investigators and seed money for developmental research programs in ovarian cancer.